Search
forLearn
5 / 801 resultslearn RH410
learn Calcium D oantothenate
learn Anasensyl
learn Selenium AAC
Research
5 / 1000+ results
research New hair care ingredients
Several companies launched new hair care ingredients in 2011 to improve conditioning, color retention, combability, and heat protection.
research Feature identification of skin diseases and laser therapy with a portable optical coherence imaging system
A portable imaging system shows promise for diagnosing skin diseases and checking laser treatment effects.
research Developing Optical Biometrics Using Optical Coherence Tomography for Medical Screening and Diagnosis
OCT can effectively screen and diagnose various medical conditions non-invasively.
research 41551 Feasibility of using an integrated RCM-OCT device to identify thin Basal Cell Carcinomas amenable to ablative therapy with a Er:YAG laser: A Prospective Observational Study
research To Better “Serve” Your Patient’s Comfort
Improve patient comfort during medical care.
Community Join
5 / 1000+ resultscommunity Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community SCUBE 3 (the last hair bender)
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
community PP405 (Everychem 3HP) Anecdotes - Please assemble and share your story
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.